SEARCH

SEARCH BY CITATION

References

  • 1
    Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881891.
  • 2
    Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102: 2228.
  • 3
    Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141148.
  • 4
    Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006;61:11621172.
  • 5
    Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599609.
  • 6
    Cox L. Allergen immunotherapy and asthma. Efficacy, safety, and other considerations. Allergy Asthma Proc 2008;29:580589.
  • 7
    Di Rienzo V, Musarra A, Sambugaro R, Minelli M, Pecora S, Canonica GW et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005; 35:560564.
  • 8
    Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 2003;5:777781.
  • 9
    Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851857.
  • 10
    Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101:206211.
  • 11
    Dahl R, Kapp A, Colombo G, De Monchy JG, Rak S, Emminger W et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434440.
  • 12
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802809.
  • 13
    Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:13381345.
  • 14
    Wahn U, Tabar A, Kuna P, Halken S, Montagut A, De Beaumont O. Efficacy and safety of 5 grass pollen subllingualimmunotherapy in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160166.
  • 15
    Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179186.
  • 16
    Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig F, Klimek L et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167173.
  • 17
    Canonica GW, Baena Cagnani C, Bousquet J, Bousquet PJ, Passalacqua G, Potter P et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317324.
  • 18
    Protocollo n. H1.2008.0046307 del 22.12.2008; Oggetto: Regole 2009, DGR n. VIII/8501 del 26 novembre 2008. Aggiornamento elenco farmaci tipologia 4 (farmaci per la terapia iposensibilizzante).
  • 19
    Brozek JL, Baena Cagnani C, Canonica GW, Bonini S et al. Methodology for development of the allergic rhinitis and its impact on asthma guideline 2008 update. Allergy 2008;63:3846.
  • 20
    Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen. Allergy 1994;49:309313.
  • 21
    Feliziani V, Lattuada G, Parmiani S, Dall’Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995;23:173178.
  • 22
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in parietaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995;5:2530.
  • 23
    Clavel R, Bousquet J, Andre’ C. Clinical efficacy of sublingual swallow immunotherapy: a double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998;53:493498.
  • 24
    Horak F, Stubner UE, Berger U, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract: a short term double blind study. J Invest Allergol Clin Immunol 1998;8:165171.
  • 25
    Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andrè C et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998;53:662671.
  • 26
    Hordijk GJ, Antwelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract: a double blind placebo controlled study. Allergol Immunopathol 1998;26:234240.
  • 27
    Passalacqua G, Albano M, Fregonese L, Riccio AM, Pronzato C et al. Clinical and immunological effects of a rush sublingual immunotherapy to parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999;104:964968.
  • 28
    Purello D’Ambrosio F, Gangemi S, Isola S, La Motta N, Puccinelli P, Parmiani S et al. Sublingual immunotherapy: a double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999;54:968973.
  • 29
    Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S et al. Sublingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999;54:819828.
  • 30
    La Rosa M, Ranno C, Andre’ C, Carat F, Tosca M, Canonica GW et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425432.
  • 31
    Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol 1999;9:305313.
  • 32
    Caffarelli C, Sensi LG, Marcucci F, Cavagni C. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55:11421147.
  • 33
    Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madr) 2001;29:238244.
  • 34
    Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Parmiani S et al. Sublingual immunotherapy in tree pollen allergy. Double blind, placebo controlled study with a biologically standardized extract of treee pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001;29:103110.
  • 35
    Lima MT, Wilson D, Pitkin L, Roberts A, Nouri Aria K, Jacobson M et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32:507514.
  • 36
    Andrè C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J et al. A double blind placebo controlled evaluation of SLIT with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003;131:111118.
  • 37
    Pajno G, Vita D, Caminiti D, Parmiani S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003;33:16411647.
  • 38
    Wuthrich B, Bucher C, Jorg W, Bircher A, Eng P, Schneider Y et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003;13:145148.
  • 39
    Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004;59:498504.
  • 40
    Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004;14:831837.
  • 41
    Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004;59:12851293.
  • 42
    Bowen T, Greenbaum J, Charbonneau Y, Hebert J, Filderman R, Sussman G et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004;93:425430.
  • 43
    Valovirta E, Jacobsen L, Savolainen A. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:11771183.
  • 44
    Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME et al. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madr) 2006;34:194198.
  • 45
    Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185190.
  • 46
    Röder E, Berger MY, Hop WC, Bernsen RM, De Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007;119:892898.
  • 47
    Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabie-Bouchat YP et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007;142:239246.
  • 48
    Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Yamamoto H, Kunii N et al. A Randomized Controlled Trial of Sublingual Immunotherapy for Japanese Cedar Pollinosis. Int Arch Allergy Immunol 2007;146:7684.
  • 49
    De Blay F, Barnig C, Kanny G, Purohit A, Leynadier F, Tunon de Lara JM et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2007;99:453461.
  • 50
    Moreno-Ancillo A, Moreno C, Ojeda P, Domínguez C, Barasona MJ, García-Cubillana A et al. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. J Investig Allergol Clin Immunol 2007;17:399405.
  • 51
    Mosges R, Buning HJ, Hessler G, Gotz G. SLIT in pollen induced seasonal rhinitis and conjuncivitis: a randomized controlled trial. Acta Dermatoven APA 2007;16:143150.
  • 52
    Panzner P, Petrás M, Sýkora T, Lesná I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med 2008;102:12961304.
  • 53
    Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H et al. A Randomized Double-Blind Comparative Study of Sublingual Immunotherapy for Cedar Pollinosis. Allergol Int 2008;57:265275.
  • 54
    Pfaar A, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008;100:256263.
  • 55
    Guerra L, Compalati E, Rogkakou A et al. Randomized open comparison of the safety of SLIT in a no updosing and traditional updosing schedule in patients with parietaria allergy. Allergol Immunopathol 2006;34:8283.
  • 56
    Rodriguez F, Boquete M, Ibanez MD, De La Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing - a new treatment schedule. Int Arch Allergy Immunol 2006;140:321326.
  • 57
    Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007;62:958961.
  • 58
    Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005;115:11841188.